Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.

Sriram BalasubramanianBrendan HodkinsonStephen J SchusterNathan H FowlerJudith TrotmanGeorg HessBruce D ChesonMichael SchafferSteven SunSanjay DeshpandeJessica VermeulenGilles SallesAjay K Gopal

Published in: Cancer medicine (2021)

NCT01779791.

Keyphrases

acute lymphoblastic leukemia
acute myeloid leukemia
multiple myeloma
hodgkin lymphoma
diffuse large b cell lymphoma
genome wide
chronic lymphocytic leukemia
bioinformatics analysis
copy number